Pipeline: Patented, Biomarker-driven Liquid Biopsy Technology

🚀 Biolink Therapeutics is on the brink of transforming cancer diagnostics in India and beyond! BioLink is collaborating with a U.S.-based startup to license an innovative, patented, biomarker-driven liquid biopsy platform. This advanced technology enables rapid, point-of-care cancer screening—including lung, breast, colorectal, and prostate cancers—with results available in just 15 minutes.

🛑 While AI-powered cancer detection platforms may sound revolutionary, they fall short where it matters most—real-world accessibility and affordability. These models still rely on costly imaging techniques, invasive biopsies, and centralized lab infrastructure, making them impractical for point-of-care screening in low-resource or rural settings. Despite the AI layer, the underlying testing methods remain expensive, time-consuming, and out of reach for the masses.

🔥 Biolink Therapeutics brings a true breakthrough: a 15-minute, non-invasive, liquid biopsy test for early detection of lung, breast, colorectal, and prostate cancers—right at the point of care. This technology is biomarker-driven, field-ready, and validated on over 5,000 patient samples, ensuring both accuracy and scalability. With no need for high-end equipment or lab setups, this patented technology is tailor-made for the Indian healthcare landscape following clinical trial and its regulatory approval —bridging the gap between innovation and impact. Biolink is considering one of the top incubators in India to start its journey towards solving long waited unmet solutions against cancer screening at point-of-care setting. 

As we meet with VCs, we're not pitching another AI tool for cancer detection—we're going to deliver a revolutionary cancer detection screening kit that can save lives where it matters most.